Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
Funds raised will be used to develop technology and foster healthcare partnerships
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
The committee unanimously decided to confer the Lifetime Achievement Award to Kiran Mazumdar-Shaw for her monumental contributions as a global leader in biotechnology innovation and entrepreneurship
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
One in two women with advanced ovarian cancer has an HRD-positive tumor
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
The ANDA was filed as 'First to File' submission on NCE-1 date.
Subscribe To Our Newsletter & Stay Updated
